Answers are grounded in this paper and cite their sources.
Objective: This study aimed to develop and validate simple, sensitive, and cost-effective UV-Visible and first-derivative spectrophotometric methods for the quantitative determination of chlorpromazine in pharmaceutical dosage forms.Methods: The UV-Visible spectrophotometric method was performed at 254 nm, whereas the first-derivative spectrophotometric method was evaluated at wavelengths of 247 nm and 261 nm. Both methods were comprehensively validated according to ICH Q2(R1) guidelines with respect to linearity, accuracy, precision, limit of detection and limit of quantification.Results: Linearity was achieved over the concentration range of 1-25 μg/mL for all proposed procedures. The developed methods demonstrated satisfactory accuracy, with relative error values ranging from -1.87% to 6.64%, and acceptable precision, with relative standard deviation values ranging from 0.04% to 8.64% across intra-day and inter-day evaluations. The limits of detection (LOD) and quantification (LOQ) were calculated as 0.29 μg/mL and 0.89 μg/mL, respectively. The first-derivative spectrophotometric approach provided improved spectral resolution and reduced the influence of potential spectral overlap from formulation components. The validated methods were successfully applied to the determination of chlorpromazine in tablet and ampoule pharmaceutical preparations.Conclusion: The obtained results indicate that the proposed spectrophotometric methods provide rapid, reliable and economical alternatives for routine pharmaceutical quality
No takes yet. Share an insight, caveat, or question.
Kaya et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: